Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.53 |
| ▸ | ACACB | O00763 | 7/20 | 0.53 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.43 |
| ▸ | ACACA | Q13085 | 2/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14919198 | 0.81 | EPHX2 (0.64) | EPHX2ACACBADRA1DADRA1AADRA1B | |
| SCHEMBL15469500 | 0.79 | EPHX2 (0.52) | EPHX2ACACBADRA1DADRA1AADRA1B | |
| SCHEMBL3491735 | 0.77 | EPHX2 (0.55) | EPHX2ACACBACACA | |
| SCHEMBL1115206 | 0.77 | EPHX2 (0.50) | EPHX2ACACBADRA1DADRA1AADRA1B | |
| SCHEMBL13339752 | 0.76 | ACACB (0.49) | EPHX2ACACBADRA1DADRA1AADRA1B | |
| Hydrochloric Acid SCHEMBL3493117 | 0.75 | ACACB (0.48) | EPHX2ACACBADRA1DADRA1AADRA1B | |
| SCHEMBL12410038 | 0.73 | KDM4E (0.36) | EPHX2ADRA1DADRA1AADRA1BSIGMAR1 | |
| SCHEMBL23928898 | 0.73 | EPHX2 (0.54) | EPHX2ACACBADRA1DADRA1AADRA1B | |
| SCHEMBL21617954 | 0.72 | ACACB (0.46) | EPHX2ACACBADRA1DADRA1AADRA1B | |
| SCHEMBL3494495 | 0.72 | ACACB (0.51) | EPHX2ACACBADRA1DADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166124-A1 | TRICYCLIC SPIROCYCLE DERIVATIVES AND METHODS OF USE | MCCORMICK KEVIN D | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166124-A1 | TRICYCLIC SPIROCYCLE DERIVATIVES AND METHODS OF USE | GPR119, TRPV1, NR3C2 | EPHX2 2824/4885ACACB 122/4885ADRA1D 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.